We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Futures Down on Trade Woes; Claims & Earnings Look Good
Read MoreHide Full Article
Thursday, May 23, 2019
Pre-market futures are once again in the red this morning, following Asian markets tumbling overnight. The trade issue on either side of the Pacific Ocean — especially with regard to the tech sector — continues to wallow in something close to turmoil at this hour, as the trade war between the U.S. and China shows no signs of ending soon.
A spokesperson from China’s Commerce Ministry said that trade talks between the top two economies in the world may resume, but only after the U.S. addresses its “wrong actions.” Contrast this with the happy talk we were hearing just a few short weeks ago, when a trade agreement was “close.” Now it doesn’t even look like the G-20 summit — the next time Presidents Trump and Xi are scheduled to see each other — will produce the progress market participants had been looking for.
Initial Jobless Claims were once again solid, however: 211K new claims last week dropped by 1000 by the previous week’s unrevised total. Continuing Claims ticked up only slightly, and remain near levels from a half-century ago. The narrative of an historically robust U.S. labor market also sees no end in sight. Our next non-farm payroll report is not due until two weeks from tomorrow.
Later today, we’ll get New Home Sales data for April, along with a fresh read on the Purchasing Managers Index for May.
A fresh earnings report from Best Buy (BBY - Free Report) brought more good news, as the big-box retailer outperformed earnings estimates massively: $1.02 per share versus expectations of 88 cents, and 82 cents per share in the year-ago quarter. Revenues were in-line with expectations at $9.14 billion, and higher than the $9.11 billion a year ago. Shares are trading up another 1.3% in the early market, and are up more than 30% year to date. For more on BBY’s earnings, click here.
MedTech major Medtronic (MDT - Free Report) also outperformed expectations notably: $1.54 versus $1.46 per share on its bottom line, while sales reached $8.15 billion in the quarter, slightly ahead of estimates and the year-ago total. Shares are trading up 2.7% in pre-market trading. For more on MDT’s earnings, click here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Futures Down on Trade Woes; Claims & Earnings Look Good
Thursday, May 23, 2019
Pre-market futures are once again in the red this morning, following Asian markets tumbling overnight. The trade issue on either side of the Pacific Ocean — especially with regard to the tech sector — continues to wallow in something close to turmoil at this hour, as the trade war between the U.S. and China shows no signs of ending soon.
A spokesperson from China’s Commerce Ministry said that trade talks between the top two economies in the world may resume, but only after the U.S. addresses its “wrong actions.” Contrast this with the happy talk we were hearing just a few short weeks ago, when a trade agreement was “close.” Now it doesn’t even look like the G-20 summit — the next time Presidents Trump and Xi are scheduled to see each other — will produce the progress market participants had been looking for.
Initial Jobless Claims were once again solid, however: 211K new claims last week dropped by 1000 by the previous week’s unrevised total. Continuing Claims ticked up only slightly, and remain near levels from a half-century ago. The narrative of an historically robust U.S. labor market also sees no end in sight. Our next non-farm payroll report is not due until two weeks from tomorrow.
Later today, we’ll get New Home Sales data for April, along with a fresh read on the Purchasing Managers Index for May.
A fresh earnings report from Best Buy (BBY - Free Report) brought more good news, as the big-box retailer outperformed earnings estimates massively: $1.02 per share versus expectations of 88 cents, and 82 cents per share in the year-ago quarter. Revenues were in-line with expectations at $9.14 billion, and higher than the $9.11 billion a year ago. Shares are trading up another 1.3% in the early market, and are up more than 30% year to date. For more on BBY’s earnings, click here.
MedTech major Medtronic (MDT - Free Report) also outperformed expectations notably: $1.54 versus $1.46 per share on its bottom line, while sales reached $8.15 billion in the quarter, slightly ahead of estimates and the year-ago total. Shares are trading up 2.7% in pre-market trading. For more on MDT’s earnings, click here.
Mark Vickery
Senior Editor
Questions or comments about this article and/or its author? Click here>>
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>